Insulet (PODD) Cash from Financing Activities (2010 - 2026)

Insulet (PODD) posted Cash from Financing Activities of -$319.9 million for Q1 2026, down 341.24% on a QoQ basis from -$72.5 million in Q4 2025, and down 215.2% year-over-year from $277.7 million in Q1 2025.

Insulet (PODD) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Insulet's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$319.9 million for Q1 2026.

  • Quarterly Cash from Financing Activities fell 215.2% year-over-year to -$319.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 552.2% YoY) and the FY2025 annual result came in at -$595.3 million, down 2026.07% from the prior year.
  • Cash from Financing Activities was -$319.9 million for Q1 2026 at Insulet, down from -$72.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $277.7 million in Q1 2025 and bottomed at -$457.0 million in Q3 2025.
  • A 5-year average of -$58.7 million and a median of -$12.1 million in 2023 frame the typical range for Cash from Financing Activities.
  • Peak annual rise in Cash from Financing Activities reached 2069.5% in 2025, while the deepest fall reached 23952.63% in 2025.
  • Insulet's Cash from Financing Activities stood at -$14.5 million in 2022, then jumped by 115.17% to $2.2 million in 2023, then sank by 1045.45% to -$20.8 million in 2024, then tumbled by 248.56% to -$72.5 million in 2025, then plunged by 341.24% to -$319.9 million in 2026.
  • Business Quant data shows PODD's Cash from Financing Activities at -$319.9 million in Q1 2026, -$72.5 million in Q4 2025, and -$457.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 17.31 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn -1.51 Bn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn -888.00 Mn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn -260.00 Mn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -451.20 Mn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn -25.00 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn 21.00 Mn
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn -26.93 Mn
10 Insulet 11.52 Bn 11.04 Bn 529.10 Mn -319.90 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -319.90 Mn
Mar 31, 2026 -319.90 Mn
Dec 31, 2025 -72.50 Mn
Dec 31, 2025 -72.50 Mn
Sep 30, 2025 -457.00 Mn
Sep 30, 2025 -457.00 Mn
Jun 30, 2025 -343.50 Mn
Jun 30, 2025 -343.50 Mn
Mar 31, 2025 277.70 Mn
Mar 31, 2025 277.70 Mn
Dec 31, 2024 -20.80 Mn
Dec 31, 2024 -20.80 Mn
Sep 30, 2024 -1.90 Mn
Sep 30, 2024 -1.90 Mn
Jun 30, 2024 8.80 Mn
Jun 30, 2024 8.80 Mn
Mar 31, 2024 -14.10 Mn
Mar 31, 2024 -14.10 Mn
Dec 31, 2023 2.20 Mn
Dec 31, 2023 2.20 Mn